Biomaterial Database

Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. 2016

R Navari

Cancer Care Program Central and South America, World Health Organization, Indiana University School of Medicine South Bend, Indiana, USA. rmnavari@gmail.com.

Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical issue which affects patients' quality of life as well as treatment decisions. Significant improvements in the control of CINV have occurred in the past 15 years with the introduction of new antiemetic agents: 5-HT3 receptor antagonists, tachykinin NK1 receptor antagonists and olanzapine. Aprepitant was the first NK1 receptor antagonist introduced (2003) for the prevention of CINV in combination with a 5-HT3 receptor antagonist and dexamethasone. Two additional NK1 receptor antagonists, netupitant and rolapitant, were approved by the FDA in 2014 and 2015, respectively. A description of rolapitant and its role in CINV will be presented, along with a comparison to the other NK1 receptor antagonists, aprepitant and netupitant.

UI	MeSH Term	Description	Entries
D009325	Nausea	An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000932	Antiemetics	Drugs used to prevent NAUSEA or VOMITING.	Anti-emetic,Antiemetic,Antiemetic Agent,Antiemetic Drug,Anti-Emetic Effect,Anti-Emetic Effects,Anti-emetics,Antiemetic Agents,Antiemetic Drugs,Antiemetic Effect,Antiemetic Effects,Agent, Antiemetic,Agents, Antiemetic,Anti Emetic Effect,Anti Emetic Effects,Anti emetic,Anti emetics,Drug, Antiemetic,Drugs, Antiemetic,Effect, Anti-Emetic,Effect, Antiemetic,Effects, Anti-Emetic,Effects, Antiemetic
D000970	Antineoplastic Agents	Substances that inhibit or prevent the proliferation of NEOPLASMS.	Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013141	Spiro Compounds	Cyclic compounds that include two rings which share a single atom (usually a carbon). The simplest example of this type of compound is Spiro[2.2]pentane, which looks like a bow tie.	Compounds, Spiro
D014839	Vomiting	The forcible expulsion of the contents of the STOMACH through the MOUTH.	Emesis
D064729	Neurokinin-1 Receptor Antagonists	Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.	Neurokinin 1 Receptor Antagonist,Neurokinin-1 Receptor Antagonist,Neurokinin-1 Receptor Blocker,Neuroleukin-1 Receptor Blocker,Substance P Receptor Antagonist,Substance P Receptor Blocker,Tachykinin Receptor 1 Antagonist,Tachykinin Receptor 1 Blocker,Neurokinin-1 Receptor Blockers,Neuroleukin-1 Receptor Blockers,Substance P Receptor Antagonists,Substance P Receptor Blockers,Tachykinin Receptor 1 Antagonists,Tachykinin Receptor 1 Blockers,Antagonist, Neurokinin-1 Receptor,Antagonists, Neurokinin-1 Receptor,Blocker, Neurokinin-1 Receptor,Blocker, Neuroleukin-1 Receptor,Blockers, Neurokinin-1 Receptor,Blockers, Neuroleukin-1 Receptor,Neurokinin 1 Receptor Antagonists,Neurokinin 1 Receptor Blocker,Neurokinin 1 Receptor Blockers,Neuroleukin 1 Receptor Blocker,Neuroleukin 1 Receptor Blockers,Receptor Antagonist, Neurokinin-1,Receptor Antagonists, Neurokinin-1,Receptor Blocker, Neurokinin-1,Receptor Blocker, Neuroleukin-1,Receptor Blockers, Neurokinin-1,Receptor Blockers, Neuroleukin-1